



## **Agenus to Report First Quarter 2014 Financial Results on May 8, 2014; Conference Call to Follow**

April 29, 2014

LEXINGTON, Mass.--([BUSINESS WIRE](#))--Agenus Inc. (NASDAQ: AGEN) will release its first quarter 2014 financial results before the market opens on May 8, 2014.

Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To access the live call, dial 647-426-1845. The call will also be webcast and will be accessible from the company's website at [www.agenusbio.com/webcast/](http://www.agenusbio.com/webcast/). A replay will be available approximately two hours after the call through midnight Eastern Time on May 8, 2014. The replay number is 416-915-1035, and the access code is 571716. The replay will also be available on the company's website approximately two hours after the live call.

### **About Agenus**

Agenus is an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants. Agenus' checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company's proprietary discovery engine Retrocyte Display<sup>®</sup> is used to generate fully human therapeutic antibody drug candidates. The Retrocyte Display platform uses a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells. Agenus' heat shock protein vaccines for cancer and infectious disease are in Phase 2 studies. The company's QS-21 Stimulon<sup>®</sup> adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen and includes several candidates in Phase 3 trials. Among Agenus and its partners, 22 programs are in clinical development. For more information, please visit [www.agenusbio.com](http://www.agenusbio.com), or connect with the company on [Facebook](#), [LinkedIn](#), [Twitter](#) and [Google+](#).

Retrocyte Display and QS-21 Stimulon are registered trademarks of Agenus and its subsidiaries.

### **Contact:**

Media and Investor Contact:

Agenus Inc.

Jonae R. Barnes, 617-818-2985

Vice President

Investor Relations and Corporate Communications

[jonae.barnes@agenusbio.com](mailto:jonae.barnes@agenusbio.com)